Westminster Pha Patent-Cliff Exposure & CMS Drug Spending Portfolio

Westminster Pha (US): 26 reconciled FDA prescription therapies, $8.8M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies26
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$8.8M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$7.6M
California HCAI SB 17 Filings1 WAC filings (max 704.2% 2-yr change)